A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy (PDR), a complication of diabetes that damages blood vessels in the light-sensitive retina in the back of the eye. Lucentis is used to treat wet macular degeneration as well as diabetic macula edema. The study found the treatment no less effective than the laser therapy which currently is the standard treatment for PDR.
In a RPB-supported commentary, Timothy W. Olsen, MD, notes that "this important study [...] represents a major step forward for patients with PDR by providing the ophthalmologists who manage their retinal disease with new options." But he adds a cautionary note.
November 17, 2015
Leaders of organizations that fund vision research convene in Washington, D.C. to increase collaboration and maximize the impact of research funding for sight-threatening diseases.
Dr. Alex Huang of the University of California San Diego School of Medicine will study glaucoma filtration surgeries with the aim of improving surgical success for lowering eye pressure and providing neuroprotection.
The new way to measure ocular aging opens treatment avenues for numerous eye diseases.
The American Academy of Ophthalmology (AAO) and Research to Prevent Blindness (RPB) today announced the 2023 recipients of the RPB/AAO Award for IRIS Registry Research.
RPB acknowledges the passing of a dedicated former Board member.
Patricia Ann D’Amore, PhD, MBA, is recognized for ground-breaking contributions to the field of vision research.
Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.
General Info | Grants | News & Resources |